SMi’s 3rd annual Immunogenicity will be returning to Holiday Inn Kensington Forum, London, UK on 13-14 June 2016

LONDON, UNITED KINGDOM, May 27, 2016 / — Immunogenicity 2016 will discuss hot industry topics such as integration of immunogenicity risk data to forecast clinical outcomes, personalized cancer vaccine development and much more.

SMi Group reports: Annie De Groot, CEO, EpiVax will be presenting on day 2 of the event on: “A computational pipeline for personalised cancer vaccine development”. Annie De Groot will be discussing how checkpoint inhibitors are changing cure rates for cancer and generating excitement in the cancer field. Participants will learn how personalised cancer vaccines will move the needle on cancer cures of the future.

Furthermore, Kees Melief, Chief Scientific Officer and Ronals Loggers, Chief Executive Officer, ISA Pharmaceuticals will be presenting on: “Correlation of T-cell responses inducted by therapeutic cancer vaccines with clinical responses”.

The 3rd annual event will also feature presentations and exclusive case studies on next generation biologics, immunogenic assessment techniques, a closer look at adaptive T Cells and much more.

To see the full event programme please visit:

2016 unrivalled speaker line up and confirmed attendees includes: Abzena, Accord Healthcare, Antitope Ltd, Baliopharm AG, Baxalta, Bioarctic Neuroscience, Bristol Myers Squibb, Crucell Vaccine Institute, EpiVax, Inc., F.Hoffmann-La Roche AG, Free University Of Brussels, GSK, ISA Pharmaceuticals, mAbxience, National Institute for Biological Standards and Control, Netera AS, NEXTERA AS, Pfizer Pharmaceuticals, ProImmune Ltd., Public Health England, Selecta Biosciences, SGS CEPHAC EUROPE SAS, Smithers Avanza, Teva, TIGENIX SAU, UCB, University Of Manchester, and many more

For those who are interested in attending– please note, registration will be closing in 2 weeks.

Event will also feature two must – attend post-conference workshops:

a) Approaches to standarising assays for measuring drug levels and anti drug antibodies to biotherapeutics in clinical practice (led by Hishani Kirby Associates and GSK)
b) Unwanted immunogenicity from bench to bedside (led by IPM Biotech and ImmunXperts)

Immunogenicity 2016 is sponsored by Abzena

For sponsorship enquiries, contact Alia Malick on +44 (0) 207 827 6168 or
For delegate enquiries, contact Matthew Apps on +44 (0) 207 827 6093 or

3rd annual Immunogenicity conference
13-14 June 2016
London, UK
Contact e-mail:
Contact tel: +44 (0) 207 827 6093

—- END —-
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Anna Serazetdinova
SMi Group Ltd
email us here

A computational pipeline for personalized cancer vaccine development at Immunogenicity 2016
Tagged on: